The BVOA-CHR offers a novel framework for the prospective studies on THR and on a national/international scale. Initial complication rates from the BVOA-CHR are similar to previous studies.

General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms and report owner-assessed outcomes.Methods: Entries into the British Veterinary Orthopaedic Association-Canine Hip Registry (BVOA-CHR) between September 2011 and December 2012 were reviewed separately and in conjunction with previous data. An online, owner-administered outcomes assessment questionnaire (modified from the Liverpool Osteoarthritis in Dogs (LOAD) questionnaire) was used to collect outcomes data from owners. Results:The incidence of surgeon and owner reported complications were 8.2% and 4.3% respectively. No significant association was identified between bodyweight, age, sex, breed or indication for THR and the incidence of complications. THR using the BFX cup/stem prosthesis had a significantly greater likelihood of complication compared to when using the CFX cup/stem prosthesis (p=0.002); a complication was 4.48 times more likely to occur when using the BFX cup/stem prosthesis versus the CFX cup/stem prosthesis. THR using the BFX cup/stem prosthesis had a significantly higher likelihood of complication compared to when using a hybrid prosthesis (BFX cup/CFX stem, CFX cup/BFX stem) (p=0.046); a complication was 2.85 times more likely to occur when using the BFX cup/stem prosthesis versus a hybrid prosthesis. In 95% of cases, owners described their satisfaction with the outcome of THR as 'very good' or 'good'. Conclusions:Complication rates from the BVOA-CHR are similar to previous studies. 'Surgeon' and 'clinic' are not variables in our analysis (contractual) but the data suggest that prosthesis type has a relationship with complication rate, with Biomedtrix BFX (circa 2012) having a high short-term complication rate.

Cementless THR can safely be performed in skeletally immature dogs, providing satisfactory return to normal joint function and implant survivability for at least a mean of 29.8 months.

An 11-week-old, domestic shorthair cat was presented for evaluation of a congenital right tarsal deformity. The cat was non-weightbearing lame on the right hindlimb. There was severe tarsal hyperextension and concurrent spasticity/contracture/shortening of the gastrocnemius muscle-tendon. The cat was otherwise healthy. Radiographically there was luxation of the proximal intertarsal joint and talocrural hyperextension. Treatment with 10 mu/kg botulinum toxin A (Botox; Allergan) intramuscular injections directly into the gastrocnemius muscle and passive physiotherapy marginally improved the range of motion in the talocrural joint. Definitive surgical treatment with partial tarsal arthodesis produced an excellent clinical outcome. This case report demonstrates the successful treatment of a severe congenital tarsal abnormality and also documents the first clinical use of botulinum toxin in a feline patient.

TPLMOCO offers a potential treatment option and warrants further investigation for use in selected cases.